Nilotinib 150 mg (DrugBank: Nilotinib)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
8 | ハンチントン病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03764215 (ClinicalTrials.gov) | November 15, 2018 | 27/11/2018 | Nilotinib in Huntington's Disease | An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease | Huntington Disease | Drug: Nilotinib 150 MG | Georgetown University | NULL | Recruiting | 25 Years | 90 Years | All | 10 | Phase 1 | United States |